Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

International Congress on Targeted Anticancer Therapies (TAT) 2011 Presentations

Plenary Session 1: Opening Ceremony

Plenary Session 2: Targeting Mutated BRAF and KRAS

Plenary Session 3: Miscellaneous Drugs and Targets (1)

Plenary Session 4: Refining Anti-Angiogenic Therapy: Getting Over the Wall

Plenary Session 5: Targeting DNA Damage Repair Beyond PARP

Plenary Session 6: Hsp90 Inhibitors

Plenary Session 7: Metabolic Targets

  • Educational lecture: Metabolic targeting: an update on biguanides - M. Pollak, Canada (slides not available)
  • Targeting metabolism: Metformin in cancer prevention and therapy - M. Pierotti, Italy (slides not available)
  • Cancer metabolism: Drug discovery to control critical metabolic enzymes - D. Schenkein, USA (slides not available)
  • Putting cancer on a diet: Targeting glycolysis and fatty acid metabolism as therapeutic strategies - P. Nisen, USA (slides not available)

Plenary Session 8: Targeting the Androgen Axis and Other Targets in Prostate Cancer

Plenary Session 9: Methodological and Regulatory Issues in the Development of Targeted Agents

Plenary Session 10: Immunological Targets

  • Immunological targets: Basic aspects - I. Melero, Spain (slides not available)
  • It's a new world in melanoma - A.M.M. Eggermont, France (slides not available)
  • Novel strategies in the design and development of recombinant vaccines for cancer therapy - R.A. Madan, C. Palena, J.L. Gulley, J.W. Hodge, K.Y. Tsang, J.W. Greiner, J. Huang, J. Schlom (slides not available)

Plenary Session 11: Drugs Targeting the PI3K – Akt – mTOR Pathway

Plenary Session 12: Miscellaneous Drugs and Targets (2)

Plenary Session 13: Roles for Genome Sequencing in Drug Development

  • Implications of the new sequencing technologies for clinical oncology - P. Meltzer, USA (slides not available)
  • An integrated and comprehensive approach of functional and structural genomics at the era of exome and next generation sequencing in early drug development - V. Lazar, France (slides not available)

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings